clinical trial · NCT05935384
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Guardant Health, Inc.·—·recruiting·n = 470
Non-small Cell Lung CancerColorectal CancerBreast CancerGuardant360
brief summary
The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid tumors. It is necessary to collect clinical data points and treatment outcomes in order to demonstrate clinical validity for longitudinal monitoring with ctDNA and correlation of ctDNA dynamics with therapeutic response, as evaluated by standard methods, including RECIST 1.1 and CT scan measurements.
started
Oct 25, 2023
primary completion
Dec 30, 2030
completion
Dec 30, 2030
last updated
Aug 22, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol